---
title: "Karyopharm Therapeutics (KPTI) news: offering"
url: "https://aibio.space/companies/karyopharm-therapeutics/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "KPTI offering and convertible notes news: Karyopharm agrees debt and equity deals it says give $100 million of flexibility. Karyopharm Therapeutics Inc."
---

KPTI Karyopharm Therapeutics Inc. NASDAQ · United States

# Karyopharm Therapeutics (KPTI) news KPTI offering and convertible notes news

Debt Financing · 2026-09-10

## [Karyopharm gets forbearance after missed loan and note payments](https://aibio.space/news/karyopharm-gets-forbearance-after-missed-loan-note-payments/)

Lenders and noteholders agreed to forbear from enforcing remedies for a limited period. The forbearance period is set to end October 15, 2026 unless extended, and can end sooner on several triggers.

## Latest Karyopharm Therapeutics news

1. 2025-10-14 Debt Financing [Karyopharm closes recapitalization with 9.00% convertible notes and $12.5 million loan draw](https://aibio.space/news/karyopharm-closes-recapitalization-9-00-percent-convertible-notes-12-5/) Karyopharm closed a recapitalization on October 10, 2025 that borrowed $12.5 million under its term loan, issued $15.0 million of 9.00% notes due 2028 and $103.5 million of 9.00% notes due 2029, and exchanged $100.978 million of older notes. Lenders also waived specified defaults under the loan.
2. 2025-10-08 Financings [Karyopharm agrees debt and equity deals it says give $100 million of flexibility](https://aibio.space/news/karyopharm-agrees-debt-equity-deals-says-give-100-million-flexibility/) The deals combine new loans and notes, payment deferrals, debt-for-equity exchanges and a private placement of about $8.75 million. Karyopharm expects about $36 million of gross proceeds and a cash runway into the second quarter of 2026.

## Karyopharm Therapeutics at a glance

- **Ticker**: KPTI

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $65.1 million

### Related companies

- [ONCOVISTA INNOVATIVE THERAPIES INC](https://aibio.space/companies/oncovista-innovative-therapies/) OTC: OVIT
- [Parabilis Medicines](https://aibio.space/companies/parabilis-medicines/) NASDAQ: PBLS
- [Biohaven](https://aibio.space/companies/biohaven/) NYSE: BHVN
- [Sunshine Biopharma](https://aibio.space/companies/sunshine-biopharma/) NASDAQ: SBFM
- [Ionis Pharmaceuticals](https://aibio.space/companies/ionis-pharmaceuticals/) NASDAQ: IONS
- [Vericel](https://aibio.space/companies/vericel/) NASDAQ: VCEL
- [Acura Pharmaceuticals](https://aibio.space/companies/acura-pharmaceuticals/) OTC: ACUR
- [Tempest Therapeutics](https://aibio.space/companies/tempest-therapeutics/) NASDAQ: TPST

### Also on NASDAQ

- [CervoMed](https://aibio.space/companies/cervomed/) CRVO
- [Akebia Therapeutics](https://aibio.space/companies/akebia-therapeutics/) AKBA
- [MANNATECH INC](https://aibio.space/companies/mannatech/) MTEX
- [Fulcrum Therapeutics](https://aibio.space/companies/fulcrum-therapeutics/) FULC
- [Talphera](https://aibio.space/companies/talphera/) TLPH
- [Quantum Biopharma](https://aibio.space/companies/quantum-biopharma/) QNTM

## Karyopharm Therapeutics annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | [$146.1 million](https://www.sec.gov/Archives/edgar/data/1503802/000119312526049397/) | [$145.2 million](https://www.sec.gov/Archives/edgar/data/1503802/000119312526049397/) |
| Research and development | [$125.6 million](https://www.sec.gov/Archives/edgar/data/1503802/000119312526049397/) | [$143.2 million](https://www.sec.gov/Archives/edgar/data/1503802/000119312526049397/) |
| Net income (loss) | [-$196.0 million](https://www.sec.gov/Archives/edgar/data/1503802/000119312526049397/) | [-$76.4 million](https://www.sec.gov/Archives/edgar/data/1503802/000119312526049397/) |
| Cash from operations | [-$75.4 million](https://www.sec.gov/Archives/edgar/data/1503802/000119312526049397/) | [-$127.5 million](https://www.sec.gov/Archives/edgar/data/1503802/000119312526049397/) |
| Cash and equivalents | [$60.5 million](https://www.sec.gov/Archives/edgar/data/1503802/000119312526347906/) | [$62.5 million](https://www.sec.gov/Archives/edgar/data/1503802/000119312526049397/) |
| Short-term investments | [$3.2 million](https://www.sec.gov/Archives/edgar/data/1503802/000119312526347906/) | [$46.2 million](https://www.sec.gov/Archives/edgar/data/1503802/000119312526049397/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $55.0 million, plus short-term investments of $10.1 million, $65.1 million in all.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Karyopharm Therapeutics

Has Karyopharm Therapeutics raised money recently?

Our latest story on this, dated Oct 8, 2025: "Karyopharm agrees debt and equity deals it says give $100 million of flexibility". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/karyopharm-agrees-debt-equity-deals-says-give-100-million-flexibility/).

Has Karyopharm Therapeutics sold convertible notes?

Our latest story on this, dated Oct 14, 2025: "Karyopharm closes recapitalization with 9.00% convertible notes and $12.5 million loan draw". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/karyopharm-closes-recapitalization-9-00-percent-convertible-notes-12-5/).

What is the ticker symbol of Karyopharm Therapeutics?

Karyopharm Therapeutics Inc. trades under the ticker KPTI on NASDAQ.

Where is Karyopharm Therapeutics listed?

Karyopharm Therapeutics Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:25K0; LS:A40YLC; LSX:A40YLC.

What is the SEC CIK of Karyopharm Therapeutics?

The SEC Central Index Key (CIK) for Karyopharm Therapeutics Inc. is 1503802. Its filings are on SEC EDGAR.

How many shares does Karyopharm Therapeutics have outstanding?

22,681,460 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-13.

Which country or territory is Karyopharm Therapeutics listed under?

Our directory records Karyopharm Therapeutics Inc. under United States.

What does Karyopharm Therapeutics do?

Our directory classifies Karyopharm Therapeutics Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Karyopharm Therapeutics?

The ISIN recorded for Karyopharm Therapeutics Inc. is US48576U2050.

Does aibio.space cover Karyopharm Therapeutics?

aibio.space lists Karyopharm Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Karyopharm Therapeutics incorporated?

SEC records list its state or country of incorporation as DE.

What was Karyopharm Therapeutics's revenue last year?

$146.1 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.

Is Karyopharm Therapeutics profitable?

Karyopharm Therapeutics Inc. reported a net loss of $196.0 million for the fiscal year ended Dec 31, 2025, and used $75.4 million of cash in operations, per its annual report to the SEC.

How much does Karyopharm Therapeutics spend on research and development?

$125.6 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does Karyopharm Therapeutics have?

$65.1 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.

## Investor discussion: Karyopharm Therapeutics

Members talk about Karyopharm Therapeutics (KPTI). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Karyopharm Therapeutics, newest first. Each line links the filing it comes from.

1. 2026-09-11 Distress Reported that a debt obligation was accelerated. SEC Form 8-K (Items 1.01,2.04,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1503802/000119312526388621/d94769d8k.htm)
2. 2026-03-24 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1503802/000119312526120770/d125009dex991.htm)
3. 2026-03-03 Financings Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1503802/000150380226000006/kpti-20260227.htm)
4. 2026-02-19 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1503802/000119312526059349/kpti-20260218.htm)
5. 2025-10-08 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.02,2.03,3.02,5.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1503802/000119312525233983/d940170dex991.htm)
6. 2025-02-24 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1503802/000095017025025640/kpti-20250224.htm)
7. 2025-01-30 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1503802/000119312525017223/d893335d8k.htm)
8. 2024-12-16 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1503802/000095017024136598/kpti-_2025_spec_meeting-.htm)
9. 2024-12-05 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1503802/000095017024133728/kpti-_2025_spec_meeting-.htm)
10. 2024-11-05 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1503802/000095017024121076/kpti-20240930.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:KPTI on TradingView](https://www.tradingview.com/symbols/NASDAQ-KPTI/).

## SEC filings and registration

- **SEC name**: Karyopharm Therapeutics Inc.

- **CIK**: 1503802

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: KPTI (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company

- **Business address**: 85 WELLS AVENUE, NEWTON, MA, 02459

- **Phone**: 617-658-0600

- **Shares outstanding**: 22,681,460 as of 2026-08-06 (10-Q filed 2026-08-13)

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/1503802/000119312526428938/d172630d8k.htm) filed 2026-10-22
- [8-K](https://www.sec.gov/Archives/edgar/data/1503802/000119312526421025/d451522d8k.htm) filed 2026-10-14
- [8-K](https://www.sec.gov/Archives/edgar/data/1503802/000119312526395517/d141487d8k.htm) filed 2026-09-18
- [8-K](https://www.sec.gov/Archives/edgar/data/1503802/000119312526388621/d94769d8k.htm) filed 2026-09-11
- [8-K](https://www.sec.gov/Archives/edgar/data/1503802/000119312526375495/d423030d8k.htm) filed 2026-08-31
- [10-Q](https://www.sec.gov/Archives/edgar/data/1503802/000119312526347906/kpti-20260630.htm) filed 2026-08-13
- [8-K](https://www.sec.gov/Archives/edgar/data/1503802/000119312526347897/kpti-20260813.htm) filed 2026-08-13
- [8-K](https://www.sec.gov/Archives/edgar/data/1503802/000119312526326995/d71318d8k.htm) filed 2026-07-31

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001503802), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Karyopharm Therapeutics Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker KPTI, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Karyopharm Therapeutics Inc.

- **Ticker**: KPTI

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Pharmaceuticals: Major

- **ISIN**: US48576U2050

- **Other listed symbols**: GETTEX:25K0; LS:A40YLC; LSX:A40YLC

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-KPTI/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/karyopharm-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Karyopharm Therapeutics (KPTI) news: offering", 2026-10-31, https://aibio.space/companies/karyopharm-therapeutics/